Two Pd(II)and Pt(II)complexes with two pyrrol-2-carbaldehyde N-p-chlorophenylthiosemicarbazone ligands are designed and characterized showing mononuclear structures.An important pharmacological property for both compo...Two Pd(II)and Pt(II)complexes with two pyrrol-2-carbaldehyde N-p-chlorophenylthiosemicarbazone ligands are designed and characterized showing mononuclear structures.An important pharmacological property for both compounds is the high selectivity for tumor cells and a lack of activity in healthy cells.The Pd(II)compound shows a higher antitumor activity and selectivity than the Pt(II)compound.Both complexes present a variety of biological interactions:with DNA models(pBR322 and CT DNA),proteins(lysozyme and RNase)and other biological targets like proteosome.Our results show that the Pd(II)complex is a more interesting candidate for potential anticancer therapies than the Pt(II)complex,and we provide new insight into the design and synthesis of palladium compounds as potential antitumor agents.展开更多
基金supported by the following grants for the Spanish MINECO:SAF-2012-34424,CTQ2015-68779R and CTQ2015-70371-REDT。
文摘Two Pd(II)and Pt(II)complexes with two pyrrol-2-carbaldehyde N-p-chlorophenylthiosemicarbazone ligands are designed and characterized showing mononuclear structures.An important pharmacological property for both compounds is the high selectivity for tumor cells and a lack of activity in healthy cells.The Pd(II)compound shows a higher antitumor activity and selectivity than the Pt(II)compound.Both complexes present a variety of biological interactions:with DNA models(pBR322 and CT DNA),proteins(lysozyme and RNase)and other biological targets like proteosome.Our results show that the Pd(II)complex is a more interesting candidate for potential anticancer therapies than the Pt(II)complex,and we provide new insight into the design and synthesis of palladium compounds as potential antitumor agents.
